Dulac Edward J III sold $91K of NTLA
Dulac Edward J III (EVP, Chief Financial Officer) sold 8,111 shares of Intellia Therapeutics, Inc. (NTLA) at $11.25 on 2026-07-22.
How this was made
The 30-second read
Why it matters
Insider sales can be sentiment-relevant, but this disclosure provides no new business, trial, or regulatory information and the transaction size is relatively small.
Market read
Traders may note insider selling, but the filing alone is unlikely to change valuation without additional catalysts.
What to watch
The article does not state whether other insiders sold/bought, whether there were concurrent option exercises, or whether the sale was part of broader compensation timing beyond the stated lack of a 10b5-1 plan.
Background
The article is a SEC Form 4 insider transaction disclosure for Intellia Therapeutics, Inc. (NTLA).
Ticker impact
Intellia Therapeutics CFO Dulac Edward J III sold 8,111 shares in an open-market transaction worth about $91.2K, per Form 4 filed today.
Low likelihood of a sustained price move; any reaction would be limited to short-term sentiment around insider selling.
The filing is a primary-source Form 4, but the transaction value ($91.2K) is modest and the article provides no accompanying operational or guidance change.
Market effects
No direct sector read-through; this is an issuer-specific insider transaction with no clinical, regulatory, or financing update.
None indicated.
None indicated.
Counterpoint
The sale could be for personal liquidity needs and does not necessarily signal reduced confidence, especially without any accompanying negative company-specific news.
Key entities
- issuerIntellia Therapeutics, Inc.
Company whose CFO insider sale is disclosed via SEC Form 4.
- insiderDulac Edward J III
EVP and Chief Financial Officer who sold shares.
